The Combination of Immunotherapy and Chemotherapy in Treating Bladder Tumor

CAO Yan-wei,ZHAO Jun,CHEN Xiu-de

DOI: https://doi.org/10.3969/j.issn.1674-7410.2010.02.004

2010-01-01

Abstract:Objective To evaluate the treatment effect of combined chemotherapy and interleukin-12(IL- 12)gene therapy in experimental urothelial bladder cancer(UBC)models both in vitro and in vivo.Methods EJ UBC cells were transfected with recombinant IL-12 genes using a liposomal transfection agent.Pirarubicin (THP)was added to the experimental samples at a final concentration of 20 mg/L.Death rates(DR)and cellular micromorphologic changes were evaluated.Bladder tumor model was established by subcutaneous injection of EJ cells to the nude mice.Following the combinant therapy of THP and IL-12 gene injection,Tumor size and IL-12 levels were tested.Results In vitro study:DR in the THP& IL-12 gene therapy group(58.2%±15.8%)was significantly higher than groups 1(12.2%±5.6%;P=0.01)and 2(33.4%±7.8%;P= 0.046).The highest amount of apoptosis changes and necrosis was observed in group 3 under electron microscope. In vivo study:A significant tumor attenuation was found in IL-12& THP group compared with any other groups(P<0.05).Serum IL-12 levels were significantly higher in IL-12 gene groups(P<0.01).Conclusions The combination of chemotherapy and IL-12 gene therapy demonstrated a synergistic suppression on bladder tumor cells both in vitro or in vivo.Further investigations should be focused on the high sufficent transgene protocols in vivo.